我們已在上線！進一步了解

Editas Medicine

EDIT

市值 US$3.61億

2.35 USD

-0.09

3.69%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

2.35

0.00

0%

1天

-3.69%

5天

-18.97%

1個月

-13.28%

3個月

-18.4%

6個月

-29.85%

今年迄今

14.63%

1年

-40.66%

5年

-93.86%

10年

-82.28%

關於： Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

員工： 87

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 28.6%

中性 71.4%

負面 0%

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

Zacks Investment Research

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027 New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026 CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Zacks Investment Research

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.

Editas Medicine to Participate in Upcoming Investor Conferences

Zacks Investment Research

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

查看新聞排名

價格圖表採用Lightweight Charts™實作